Transcription factors including mutant p53s are not considered to be suitable druggable targets for cancer therapies; therefore, mutant p53-regulated oncogenic targets and their associated regulatory machinery will likely be the most exploitable therapeutic vulnerabilities for cancer treatment and prevention among LFS patients. This evidence concerns the gene TP53 and cancer.